Summary: Pretreatment and serial posttreatment carcino embryonic antigen (CEA) serum levels were studied with respect to the course of disease in 222 patients with colorectal cancer. The CEA values during the subsequent six years were expressed in actuarial or cumulative plots in relation to tumour-free period, time of diagnosis of recurrence and other parameters.
Introduction
precise definition of the clinical role of carcino^mbry-especially concerning the course of CEA in recurrence, onic antigen (CEA) in colorectal cancer is possible only Three P roblems *" ***** to be solved:
when statistical analyses of CEA data in correlation with 1. does preoperative CEA have additional prognostic sigclinical data in long term follow-up studies are available. nificance over histological staging of tumour spread or There are in fact relatively few studies (1,2,3) based on over other clinical data obtained immediately after prilong term follow-up with complete statistical work up, mary treatment
2. what is the distribution of lead times of CEA before and after objective evidence of recurrence?
3. what is the minimum time for routine follow-up by CEA assays necessary to detect recurrence?
The present report is a statistical analysis of the association of CEA before and after primary treatment with the course of colorectal cancer, in an attempt to answer the above questions. The report concerns 222 patients fol· lowed for one to six years. We feel that this report may contribute to final conclusions about the clinical value of CEA.
Patients and Methods
The entire patient population studied consisted of. 129 patients with histologically documented coIonic cancer and 93 patients with histologically documented cancer of the rectum. The median age was 65 years (30-95 years). The patients of both categories were treated as one group. Two hundred and five patients underwent surgery as primary treatment. In 189 of these patients the surgical treatment was intended to be curative. In the remaining patients surgery was palliative because of distant metastases prior to surgery. Tumour spread was judged according to Dukes classification (4, 5) in 188 patients. Out of these 17 had Dukes A, 99 had Dukes B and 72 had Dukes C lesions. Figure 1 shows the association with rate of recurrence in our patients. Nineteen patients received radiation therapy as primary treatment either because they refused surgery or because they were considered inoperable. Indications of residual tumour after surgery were (a) cut surfaces of resection material not free of tumour or (b) tumour remaining in situ after resection or (c) metastases detected during or prior to palliative surgery. The CEA assay CEA was measured in duplicate by a radio immunoassay as described in full earlier (6) . Briefly, the sample is incubated overnight with goat anti-CEA-antiserum and labeled CEA. The addition of the latter is delayed for some hours. The degree of inhibition was measured by the radioactivity in the residue, taking the radioactivity in the absence of unlabeled CEA as 100%. A standard dilution was constructed by adding 16 different known amounts of CEA (from zero to 75.0 Mg/1) in human normal serum (from nonsmokers), thus providing sufficient points for the construction of the inhibition curve. The CEA and the goat antiserum were prepared in our laboratory. The lower limit of sensitivity was 3.0 Mg/1. Samples resulting in a percentage of bound radioactive CEA lower than 25% over BQ were re-assayed after appropriate dilution with human normal serum. Generally, a batch of normal serum was used for three weeks and replaced at the end of this period by a batch taken from another healthy non-smoking donor. However, healthy persons can have different serum CEA values and the change from one batch of normal serum to another may introduce a shift in the measured CEA values. It is evident that for long term follow-up studies such alterations in CEA values must be avoided in a controlable way.
We have solved this problem by introducing a 'standard ñïïÃ. The reader is referred to I.e. (6) for further details. In addition, within every run 4-6 different serum pools were incorporated at various positions scattered throughout the whole series. The range of each pool had been determined by calculation of the mean value and the 95 % confidence limits obtained from results within at least 30 runs. New serum pools were only incorporated as controls after their range was established. By these measures sufficient reproducibility for a long period was obtained, which is a prerequisite for long term follow-up studies. The results from the patients' sera were not accepted if more than one of the serum pools showed values outside established ranges. Statistical analysis Statistical analysis was done on data accrued over the period before primary treatment till recurrence was clinically manifest, or in recurrence-free patients till termination of the study. Thus, the terms pretreatment and posttreatment refer to primary treat-, ment. The relationship between CEA pretreatment values and prognosis (relapse) was analyzed using the method of Kaplan & Meier (7) to produce the graphs, and the test of Mantel (8) 
CEA lowest point and lowest value
If a CEA decrease occurred the CEA lowest point was defined by the time at which during this decrease the highest of any two subsequent CEA measurements reached a minimum. This minimum was termed the CEA lowest value. If no CEA decrease occurred, the CEA lowest value was equated to the CEA pretreatment value.
CEA rise
A CEA rise was said to occur when at least two subsequent CEA measurements satisfying the following criterion were noted: if the CEA lowest value was < 5. 
CEA no fall
If neither a CEA decrease nor a CEA increase was observed, the CEA values were termed 4 no fair. These definitions were used so as to minimize on the one hand the influence of occasional outlying points and to retain on the other hand as much resolution as possible.
The statistical significance of the relationship between CEA increase and prognosis was analyzed using a method given by Clayton (9) in a different context. This method can be seen to be a generalization of the logrank test: for each time point at which a CEA increase occurred, the prognosis of the patient whose CEA increase did occur on that time was compared, using the logrank test, with the prognosis of patients who, up to that time, had not undergone a CEA increase; these separate comparisons were then combined using the Mantel-Haenszel procedure (10) . In the case of relapse as a prognostic parameter, a CEA increase occurring after the relapse was discounted in this procedure.
To get a graphic impression of the relationship between CEA increase and prognosis for those patients who, at some time during their follow-up, showed a CEA increase, the intervals between time of CEA increase and time of relapse have been displayed in the way generally used for survival times. In the same graph comparable curves are then given for patients who, within specified intervals from treatment, did not show a CEA increase, measuring relapse time from the end of the specified interval. Table 1 gives the distribution of CEA pretreatment levels for the different groups according to Dukes. (The differences between the latter groups were not significant).
Results

Association of pretreatment CEA with recurrence
Association of pretreatment CEA with recurrence taking posttreatment clinical data into consideration
The patients presented above constituted a heterogeneous group in the sense that 37 patients, i.e. a fraction of 0.16, proved to have residual tumour after primary treatment (see tab. 2). It is interesting to note that after discarding the patients with residual tumour from the analysis the differences between the groups based on their pretreatment CEA values below 19. Table 2 gives the distribution of the patients according to their pretreatment levels and the presence or absence of residual tumour. In 144 patients with a pretreatment CEA value > 4.9 jug/1 the course of posttreatment CEA was known. Among these, 20 patients had residual tumour. It will be noted that posttreatment CEA diminished in 2 patients within 100 days until it was below 5. 
Fall of posttreatment CEA in patients with residual tumour
Association of rise of CEA with subsequent tumour-free period
The bottom line in Figure 6 is an actuarial plot of tumour-free periods following a rise of posttreatment CEA. It should be pointed out that this graph involves only pa- 1.00 r tients with a positive lead time (i.e. CEA rise prior to detection of recurrence). The greatest lead time was 625 days. A fraction of 0.50 of patients showed clinical indications of recurrence within approximately 125 days after CEA rise. On the other hand, as can be seen from the intersection with the vertical axis, a fraction of about 0.22 showed first signs of recurrence at the same time that CEA started to rise. A fraction of 0.30 of patients with CEA rise did not show recurrence. For comparison the upper lines are shown referring to tumour-free periods after a given period in which no rise of CEA (i.e. CEA decrease or CEA no fall) was observed. For example, a fraction of 0.76 of 139 patients, showing no rise of CEA during a posttreatment period of 500 days, were still tumour-free after a further period of 1000 days. Comparison of the data represented by the bottom line and those presented by the upper lines demonstrates that a rise of posttreatment CEA as an indication of recurrence has a prognostic value at a highly significant level. We were therefore interested in defining the minimum follow-up by CEA assays necessary for indication of recurrence. Figure 7 shows that 1300 days after primary treatment no new increase of CEA was observed in our patients. (The last recurrence was observed at day 1611). Thus, the risk of developing recurrence after a 1300 days period of surveillance without increase of posttreatment CEA can be considered as minimal. 
Distribution of lead times in local and distant recurrences
Discussion
Pretreatment CEA
A role for pretreatment CEA in predicting prognosis is suggested by several data: There is a tendency towards higher fractions of patients with increased CEA from Dukes A to Dukes C groups (2,11-14, see also tab. 1). The Dukes classification is related to prognosis. We observed that the high prognostic significance of pretreatment CEA ( fig. 2) b. a rise of CEA, if defined by strict criteria, is highly prognostic for recurrence, c. the occurence of a 'false' rise must be taken into account. Such a rise is transient and followed by a return to baseline (15, (18) (19) (20) (21) (22) .
The curves of figures 8 and 9 indicate that both positive and negative lead times are possible and strongly suggest that a recurrence without any rise of CEA is exceptional (In disseminated breast cancer a different conclusion was reached (24) ). This rule seems to hold for both local and distant recurrences. Earlier reports (25, 26, 27) The shape of the curves in figures 8 and 9 is related both to frequency of physical examinations and sampling for CEA. The intervals were not standardized. With less frequent examinations, but shorter intervals of CEA tests, the curve would have shifted to the left, resulting in a higher mean value of positive lead time. In the reverse case a higher mean value of negative lead time would have been obtained. Although the precise shape of the curves (figs. 8 and 9) is disputable, conclusions regarding the prognostic function of CEA in detecting recurrence can be made.
Local recurrence is the only type of tumour progression which can be treated curatively. Some authors (21, 28) have studied the potential of CEA rise for early detection of local recurrence, hoping to increase in this way the benefit of secondary surgery. Of all our patients with rising CEA, a fraction of pprox. 0.05 had both local recurrence and a minimal positive lead time of 200 days. This low fraction is discouraging. Staab et al (21) presented variations of CEA suggesting that a slow rise is indicative for local recurrence. This approach, however still awaits statistical confirmation.
CEA and recurrence
Figures 5 and 6 give statistical evidence that a. a decrease or stationary posttreatment CEA does not provide any prognostic information as regards recurrencefree period, for their cooperation in this study. We are also indebted to the following physicians: A. 
